XCUR

Exicure Inc

0.8900

Nov 05 • 11:00 AM ET -0.1028 (-10.35%)

Healthcare Biotechnology USA Nano NASD

Peers: BLRX JSPR MBRX VOR CTXR TCRT ESLA ONCO INDP SCNI

Index	-
Market Cap	5.83M
Enterprise Value	4.11M
Income	-8.28M
Sales	0.00M
Book/sh	0.15
Cash/sh	0.26
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	May 22, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.81
P/C	3.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.56
Current Ratio	0.56
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.30
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	34.50% 54.97%
Sales past 3/5Y	- -
EPS Y/Y TTM	23.05%
Sales Y/Y TTM	-100.00%
EPS Q/Q	57.60%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	42.98%
Insider Trans	0.00%
Inst Own	2.09%
Inst Trans	-2.16%
ROA	-54.98%
ROE	-168.37%
ROIC	-847.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.21%
SMA50	-24.03%
SMA200	-65.93%
Trades

Shs Outstand	6.37M
Shs Float	3.73M
Short Float	1.15%
Short Ratio	0.97
Short Interest	0.04M
52W High	9.48 -90.61%
52W Low	0.88 1.69%
Volatility	12.50% 11.38%
ATR (14)	0.11
RSI (14)	35.93
Beta	3.74
Rel Volume	0.38
Avg Volume	44.13K
Volume	4,841

Perf Week	-4.79%
Perf Month	-12.75%
Perf Quarter	-33.83%
Perf Half Y	-73.43%
Perf YTD	-83.58%
Perf Year	-78.29%
Perf 3Y	-71.75%
Perf 5Y	-99.47%
Perf 10Y	-
Recom	1.00
Target Price	10.33
Prev Close	0.99
Price	0.89
Change %	-10.35%

Consensus

Strong Buy

Avg. Price Target

$10.33

Implied Upside

+1,060.7%

Analysts3incl. previous ratings

Rating Distribution2 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 13, 2021	Downgrade	CChardan Capital Markets	Buy → Neutral	$2.25 → $0.40	-55.1%
Dec 18, 2020	Initiated	BBMO Capital Markets	Outperform	$6	+574.2%
Nov 20, 2019	Initiated	GGuggenheim	Buy	$9	+911.2%

Sep-16-26 08:00AM	Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement (GlobeNewswire)
Aug-03-26 09:24AM	Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance (GlobeNewswire)
Jun-30-26 08:40AM	Exicure Announces Board and Committee Changes (GlobeNewswire) -5.45%
Jun-10-26 04:01PM	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (GlobeNewswire)
Jun-01-26 04:00PM	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q (GlobeNewswire) -6.61%
07:54PM	Loading…
Apr-22-26 07:54PM	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) (GlobeNewswire)
Apr-02-26 04:01PM	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions (GlobeNewswire)
Mar-25-26 04:18PM	Exicure, Inc. Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-05-26 07:00AM	Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant (GlobeNewswire)
Jan-21-26 07:00AM	Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings (GlobeNewswire)
Dec-08-25 04:30PM	Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting (GlobeNewswire) +8.78% +36.77%
Nov-07-25 04:00PM	Exicure, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire) -6.82%
Nov-03-25 09:00AM	New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting (GlobeNewswire)
Oct-22-25 04:15PM	Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-06-25 07:00AM	Exicure Highlights Recent Achievements and Near-term Strategic Priorities (GlobeNewswire)
04:01PM	Loading…
Aug-08-25 04:01PM	Exicure, Inc. Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 04:37PM	Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements (Business Wire) +10.37%
Aug-01-25 04:01PM	Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant (Business Wire)
Jun-27-25 04:01PM	Exicure, Inc. Reports First Quarter 2025 Financial Results (Business Wire) +6.22% +19.52%
May-28-25 04:58PM	Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q (Business Wire)
May-05-25 08:00AM	Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant (Business Wire)
Apr-22-25 09:21AM	Why Exicure Inc. (XCUR) Soared on Monday (Insider Monkey)
Apr-14-25 06:11PM	Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma (Business Wire)
Apr-11-25 07:42PM	Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) (Business Wire)
Mar-18-25 04:01PM	Exicure, Inc. Reports Full Year 2024 Financial Results (Business Wire)
Mar-13-25 04:08PM	Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia (Business Wire) +25.07%
Jan-23-25 12:17AM	CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. (Business Wire) +31.73%
Jan-22-25 04:01PM	Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. (Business Wire) -15.07%
Dec-26-24 08:08PM	Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech (Business Wire)
Dec-21-24 01:48PM	CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes (Business Wire)
04:42PM	Loading…
Dec-20-24 04:42PM	Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes (Business Wire) +18.61%
Nov-14-24 04:01PM	Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results (Business Wire) +16.48% -8.81%
Sep-18-24 04:01PM	Exicure, Inc. Receives Extension from Nasdaq Hearings Panel (Business Wire) +71.62%
Sep-09-24 06:53PM	Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation (Business Wire)
Aug-26-24 09:08AM	Exicure, Inc. Announces 1-for-5 Reverse Stock Split (Business Wire) -9.52%
Aug-19-24 10:31AM	Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting (Business Wire) +9.83%
Aug-15-24 10:31AM	Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting (Business Wire)
Aug-13-24 04:01PM	Exicure, Inc. Reports Second Quarter 2024 Financial Results (Business Wire) -25.57%
Aug-08-24 04:27PM	Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics (Business Wire) +6.48%
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +33.76%
Aug-01-24 04:01PM	Exicure, Inc. Receives Positive Listing Determination from Nasdaq (Business Wire) +12.97%
Jul-26-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-17-24 09:53PM	XCUR Stock Earnings: Exicure Reported Results for Q1 2024 (InvestorPlace)
04:01PM	Exicure, Inc. Reports First Quarter 2024 Financial Results (Business Wire)
Jun-06-24 09:52PM	XCUR Stock Earnings: Exicure Reported Results for Q4 2023 (InvestorPlace) -5.30% -16.35%
04:01PM	Exicure, Inc. Reports Full Year 2023 Financial Results (Business Wire)
May-29-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +11.05%
May-23-24 04:01PM	Exicure, Inc. Received Nasdaq Notice of a Delisting Determination (Business Wire) -26.34%
May-16-24 09:52PM	XCUR Stock Earnings: Exicure Reported Results for Q3 2023 (InvestorPlace)
04:08PM	Exicure, Inc. Reports Third Quarter 2023 Financial Results (Business Wire)
Apr-22-24 04:01PM	Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K (Business Wire)
Feb-06-24 07:05AM	Exicure and Bluejay sign hepatitis treatment development deal (Pharmaceutical Business Review) +27.59%
Feb-05-24 04:01PM	Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis (Business Wire)
Dec-08-23 08:40AM	Why Is Exicure (XCUR) Stock Up 57% Today? (InvestorPlace) +28.59%
Nov-28-23 04:01PM	Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q (Business Wire) -6.00%
Aug-23-23 09:48AM	Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors (Business Wire)
Aug-11-23 04:01PM	Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-14-23 04:01PM	Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +7.94%
May-26-23 04:01PM	Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives (Business Wire)
May-19-23 04:01PM	Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q (Business Wire) -9.13%
May-04-23 04:01PM	Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld (Business Wire)
Apr-27-23 07:00AM	Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors (Business Wire)
Mar-27-23 04:01PM	Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update (Business Wire) -5.26% -10.84%
Feb-24-23 05:10PM	Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors (Business Wire) +7.02%
Dec-14-22 05:00AM	Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements (Business Wire)
Nov-14-22 04:01PM	Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) -8.73%
Sep-26-22 04:01PM	Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives (Business Wire) +10.39% -17.06%
Sep-01-22 07:00AM	Exicure Announces Presentation at Chardans 6th Annual Genetic Medicines Conference (Business Wire)
Aug-15-22 04:01PM	Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress (Business Wire)
Jul-20-22 04:01PM	Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire)
Jun-29-22 12:00PM	Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split (Business Wire) -27.81%
May-27-22 04:01PM	Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders (Business Wire) +6.69%
May-17-22 07:00AM	Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference (Business Wire) +9.21%
May-16-22 04:01PM	Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress (Business Wire) -6.19%
May-10-22 07:21PM	Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium (Business Wire) +6.19% +7.24%
May-09-22 07:00AM	Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference (Business Wire) -19.21%
Mar-25-22 04:15PM	Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress (Business Wire) -16.69% -24.15%
Feb-04-22 11:25AM	Chicago CEO steps down after just two months on the job (American City Business Journals)
07:00AM	Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors (Business Wire)
Jan-05-22 01:38PM	Neville Rodie & Shaw Inc Buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk ... (GuruFocus.com) -9.05%
Dec-31-21 07:07PM	Upcoming Deadline Reminder: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (NewMediaWire) +11.38%
06:02PM	Exicure Class Action Reminder (NewMediaWire)
02:53PM	UPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (PR Newswire)
01:15PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Dec-30-21 05:57PM	Exicure Shareholder Notice (NewMediaWire)
03:31PM	Shareholder Action Notice: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (NewMediaWire)
10:00AM	SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Dec-29-21 11:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exicure, Inc. - XCUR (PR Newswire) -8.95%
05:57PM	Exicure Shareholder Alert (NewMediaWire)
04:30PM	Shareholder Action Alert: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (NewMediaWire)
10:45AM	INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Dec-28-21 05:57PM	Exicure Deadline Alert (NewMediaWire)
02:50PM	Investor Action Reminder: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (NewMediaWire)
10:00AM	INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Dec-27-21 03:16PM	Shareholder Action Notice: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (NewMediaWire)
11:00AM	SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Dec-26-21 08:32AM	Exicure Class Action Reminder (NewMediaWire)
Dec-24-21 06:13PM	Exicure Shareholder Notice (NewMediaWire)
01:56PM	Shareholder Action Alert: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (NewMediaWire)
10:40AM	INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Exicure HiTron Inc.	10% Owner	Jan 21 '26	Sale	4.50	258,367	1,162,652	1,598,947	Jan 21 12:46 PM
Exicure HiTron Inc.	10% Owner	Jan 16 '26	Sale	4.50	734,747	3,306,362	1,857,314	Jan 20 02:09 PM
Exicure HiTron Inc.	10% Owner	Jan 07 '26	Sale	4.50	741,272	3,335,724	2,592,061	Jan 08 08:42 PM
SANGSANGIN INVESTMENT & SECURI	10% Owner	Dec 08 '25	Sale	8.71	433,332	3,774,322	0	Dec 10 08:51 PM

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

CEOMr. Jungsoo Kim

Interim CFO & SecretaryMr. Gyuyeob Lee

Chief Operating OfficerMr. Young Seung Ko

Chief Accounting OfficerMr. Joshua Miller

Head of Preclinical Research & Translational MedicineDr. Devki Sukhtankar Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XCUR

Exicure Inc

Upgrade your Finviz experience